Need for treatment escalation · infants with bronchiolitis
Summary of findings table ‐ High‐flow nasal cannula probably leads to lower need for treatment escalation compared with standard oxygen therapy (low‐flow) (moderate certainty).
1 finding from 1 review
Duration of oxygen therapy (hours) · infants with bronchiolitis
1 finding from 1 review
Chronic lung disease · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of any form of respiratory support (any form of non‐invasive respiratory support with or without supplemental oxygen) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
ICU length of stay (selenium) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Length of hospital stay · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Adverse events · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Death · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Treatment failure · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
Summary of findings table ‐ High flow nasal cannula (HFNC) may leads to lower treatment failure compared with low flow nasal cannula (LFNC) (low certainty).
1 finding from 1 review
Weight loss of at least 5% at ≥ 12 months ‐ not measured · overweight and obese participants without T2DM (weight‐reducing phase followed by weight maintenance phase)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality ‐ not measured · overweight and obese participants without T2DM (weight‐reducing phase followed by weight maintenance phase)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in DBP (mmHg) at ≥ 12 months · overweight and obese participants without T2DM (weight‐reducing phase followed by weight maintenance phase)
1 finding from 1 review
LDL cholesterol (mmol/L), change from baseline · overweight and obese participants without T2DM (weight‐reducing phase followed by weight maintenance phase)
1 finding from 1 review
Constipation at 3 to < 12 months ‐ not measured · overweight and obese participants without T2DM (weight‐reducing phase followed by weight maintenance phase)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in weight (kg) · overweight and obese participants with T2DM (weight‐reducing phase followed by weight‐maintenance phase)
2 findings from 1 review
Weight loss of at least 5% at ≥ 12 months ‐ not measured · overweight and obese participants with T2DM (weight‐reducing phase followed by weight‐maintenance phase)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality ‐ not measured · overweight and obese participants with T2DM (weight‐reducing phase followed by weight‐maintenance phase)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in DBP (mmHg) at ≥ 12 months · overweight and obese participants with T2DM (weight‐reducing phase followed by weight‐maintenance phase)
1 finding from 1 review
HbA1c (glycated haemoglobin), change · overweight and obese participants with T2DM (weight‐reducing phase followed by weight‐maintenance phase)
1 finding from 1 review
LDL cholesterol (mmol/L), change from baseline · overweight and obese participants with T2DM (weight‐reducing phase followed by weight‐maintenance phase)
1 finding from 1 review